|Surname: Alexandrova (Aleksandrova by passport)|
|Cell phone number with international prefix: +359889654253|
|Affiliation: Institute of Experimental Morphology, Pathology and Anthropology with Museum –Bulgarian Academy of Sciences (IEMPAM-BAS)|
|Gender: F X M □|
|Year of the PhD title: 2009|
|Personal web page: http://|
|Previous COST participation: No □ Yes X MP1301, TD1304|
List of 10 selected publications within last 5 years
|1. Kaloyanov N., Alexandrova R., Wesselinova D.W., Mayer-Figge H., Sheldrick W.S., Dimitrov G.D. Self-assembly of novel molecular complexes of 1,10-phenanthroline and 5-amino-1,10-phenanthroline and evaluation of their in vitro antitumour activity. Eur. J. Med. Chem., 46 (6), 2011, 1992-1996.
|2. Mosoarca, E.M., I. Pantenburg, R. Tudose, G. Meyer, N. C. Popa, A. Han, R. Alexandrova, R. Kalfin, Wolfgang Linert and Otilia Costisor. Synthesis, structure and cytotoxic activity of mixed-valent Cu(I)/Cu(II) salt containing a pyrazolone derivative as ligand. Inorganica Chimica Acta, 2011, 370 (1), 460-468.
3. Alexandrova R., Zhivkova T., Alexandrov M., Miloshev G., Georgieva M., Pantcheva I., Mitewa M. Cytostatic and cytotoxic properties of monensic acid and its biometal (II) complexes against human tumor / non-tumor cell lines. Cent. Eur. J. of Chem., 2012, 10 (5), 1464 – 1474.
|4. Culita D.C., Alexandrova R., Dyakova L., Marinescu G., Patron L., Kalfin R., Alexandrov M. Evaluation of Cytotoxic and Antiproliferative Activity of Co(II), Ni(II), Cu(II) and Zn(II) Complexes with Meloxicam on Virus – Transformed Tumor Cells. Revista de Chimie, 2012, 63 (4), 384-389.
5. Pantcheva I., Alexandrova R., Zhivkova T. and Mitewa M. In vitro activity of biometal(II) complexes of monensin against virus-induced transplantable animal tumors. Biotechnology & Biotechnological Equipment, 2013, 27 (2), 3703 – 3708.
|6. Dyakova, Lora, Daniela-Cristina Culita, Gabriela Marinescu, Marin Alexandrov, Reni Kalfin, Luminita Patron, Radostina Alexandrova. Metal (ZnII, CuII, NiII) complexes of Ursodeoxycholic acid as putative anticancer agent. Biotechnology & Biotechnological Equipment, 2014, 28(3), 543-551.
|7.Dyakova L., Culita D.., Zhivkova T., Georgieva M., Kalfin R., Miloshev G., Alexandrov M., Marinescu G., Patron L. and Alexandrova R. 3d Metal complexes with meloxicam as terapeutic agents in fight against human glioblastoma multiforme and cervical carcinoma. Biotechnology & Biotechnological Equipment, 2015, 29(6), 1190-1200; DOI: 10.1080/13102818.2015.1074873,|
|8. Alexandrova R., Zhivkova T., Simeonov N., Mosoarca E.-M., Tudose R., Costisor O., Kalfin R.. Effect of mixed ligand copper (II) complex on viability and proliferation of sensitive and resistant human cancer cells. Comptes rendus de l’Academie bulgare des Sciences, 2015, Vol 68, No6, pp.789-794;
|9. Kulchitsky, V., R. Alexandrova, K. Suziedelis, S. Paschkevich, V. Potkin. Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment. Recent Patents on Nanomedicine, 2016, 4, 82-89.
|10. Grabchev, S. Yordanova, E. Vasileva-Tonkova, M. Cangiotti, A. Fattori, R. Alexandrova, S. Stoyanov and M. F. Ottaviani. A novel benzofurazan-cyclam conjugate and its Cu(II) complex: Synthesis, characterization and in vitro cytotoxicity and antimicrobial activity. Dyes and Pigments, 2016, 129, 71-79.
Main skills and expertise (up to 5)
|1. Establishment and characterization (morphological, functional) of primary cultures and permanent cell lines (including hybridoma clones secreting monoclonal antibodies; drug resistant cell cultures), cell culturing|
|2. Evaluation of biological activity (influence on cell viability and proliferation, antitumor activity) of metals, synthetic compounds and natural products in vitro and in vivo|
|3. Еxpertise in the fields of Cancer Biology, Experimental oncology and Oncopharmacology (confirmed by PhD thesis, project management, articles; teaching “Introduction in experimental oncology” and “Molecular mechanisms of cancerogenesis and new strategies in cancer prevention, diagnosis and treatment” since 2012; Associate member of Bulgarian Association of medical Oncology and European Society of Medical Oncology; Member of the Editorial Board of Studia Oncologica, Bulgaria, etc); Virology (MSc and PhD in Virology, teaching Virology in Faculty of Biology, Sofia University “St. Kliment Ohridski” (FB –SU) since 1998); Immunology (confirmed by PhD thesis, projects, articles; secretary/treasurer of Bulgarian Society of Immunology; teaching Immunology in BF-SU in the period 1998 – 2004 and “Viruses and Immunity” in PhD School of Bulgarian Academy of Sciences (PhD School BAS) since 2012); Cell Biology and Morphology (Associate Professor in Morphology, Member of the Editorial Board of “Acta Morphologica et Anthropologica”, Bulgaria); Genetics (teaching Genetics in BF-SU since 2007); Human Biology and Medicinal Parasitology (teaching Human Biology including Medicinal Parasitology in Faculty of Medicine – SU in the period 2011-2014); Tissue engineering (managing projects in the field of bone tissue engineering, participation in COST Action MP1301; lecturing “Introduction in Cell and Tissue Engineering” in PhD School – BAS since 2012), Nanomedicine and Nanooncology (articles, projects), Biological activity of metals, synthetic compounds and natural products (PhD thesis, project management, articles, MC member in COST Action TD1394; organization of ten Workshops in this field – see http://www.iempam.bas.bg/ section Journals), Biochemistry and Microbiology (Bachelor in Biochemistry and Microbiology, BF – SU)|
|4. Organization and management of scientific events (workshops, summer schools, courses) – some of them are presented in the web page of IEMPAM – BAS: http://www.iempam.bas.bg/ – Section Journals – “Experimental Models and Methods in Biomedical Research” and “Biological Activity of Metals, Synthetic Compounds and Natural Products”.|
Main equipment/facilities available in the participants’ lab (up to 5)
|1. For cell culturing (laminar boxes, CO2 incubators, inverted light microscopes, centrifuges, Bank for cell cultures and viruses, etc.)|
|2. For evaluation of cell viability and proliferation, cytopathological changes (ELISA reader, fluorescence microscope, electron microscope, etc)|
|3. For histology/histopathology, immunohistochemistry / immunocytochemistry investigations|
|4. For DNA/RNA and protein isolation and analyses (equipment for PCR, DNA/RNA electrophoresis, SDS electrophoresis and Western Blotting, microcentrifuges, etc.)|
|5. For statistical analysis and presentation of experimental data|
Short personal activity proposal for the COST Action CA15135 (max 1000 characters)
|Evaluation of cytotoxic/cytostatic effects and antitumor activity of new compounds/molecules.
A wide range of cell cultures [primary cultures and permanent cell lines; cancer and non-cancer cells; animal and human cells; cell cultures established from cancers of various origin, histological type, etiology; drug-sensitive and drug-resistant cancer cells] will be used as model systems in our studies.
The investigations will be performed by short-term (2-4 to 96 h, with monolayer 2D cell cultures) and long-term (16-18 to 30-40 days; with 3D cancer cell colonies) experiments using methods with different molecular/cellular targets and mechanisms of action such as MTT assay, neutral red uptake cytotoxicity assay, crystal violet staining, double staining with acridine orange and propidium iodide, LDH cytotoxicity assay, TUNEL test, Annexin V propidium iodide staining, colony-forming method, etc.
Preparation of experimental and review articles, presentations and other educational materials.
Organizing a COST CA 15135 Meeting/Workshop in Sofia, Bulgaria.
Work Group preference: score from 1 (preferred) to 4 (not preferred)
|Work Group of the CA15135 COST Action||Score|
|WG1: Development of new chemical entities|
|WG2: Selection of biological targets and assessment of biological data||X|
|WG3: Development of chemical databases|
|WG4: Development of Computational methods for multiple ligand design and discovery|